uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
beta-glucans reduce LDL cholesterol in patients with myasthenia gravis
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Clinical Neurophysiology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Clinical Neurophysiology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Clinical Neurophysiology.
2013 (English)In: European Journal of Clinical Nutrition, ISSN 0954-3007, E-ISSN 1476-5640, Vol. 67, no 2, p. 226-227Article in journal (Refereed) Published
Abstract [en]

We aimed at evaluating whether beta-glucans could improve low-density lipoprotein (LDL) cholesterol levels and/or glycemic control in patients with myasthenia gravis (MG), in whom statins usually have muscle-related side effects. Fifty-nine MG patients participated in the study and received a daily dietary supplement of 3 g of beta-glucans during 8 weeks. Body mass index (BMI) and blood sample analysis of lipid and glucose status were performed before and after 8 weeks intake of beta-glucans. In the 52 patients who completed the study, there was a significant reduction in total cholesterol, LDL, ApoA1 and ApoB (all P<0.003). However, glycemic control and BMI were unaltered. The present study indicates that 8 weeks daily intake of 3 g of beta-glucans significantly reduces total cholesterol, LDL, ApoA1 and ApoB in MG patients. beta-glucans may therefore be of value in improving lipid status in MG patients, without the muscle-related side effects accompanied by statins.

Place, publisher, year, edition, pages
2013. Vol. 67, no 2, p. 226-227
Keywords [en]
beta-glucans, LDL cholesterol, myasthenia gravis, glycemic control
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:uu:diva-197408DOI: 10.1038/ejcn.2012.191ISI: 000315016300018OAI: oai:DiVA.org:uu-197408DiVA, id: diva2:613564
Available from: 2013-03-28 Created: 2013-03-25 Last updated: 2017-12-06Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full text

Authority records BETA

Haggård, LinneaPunga, Anna Rostedt

Search in DiVA

By author/editor
Haggård, LinneaPunga, Anna Rostedt
By organisation
Clinical Neurophysiology
In the same journal
European Journal of Clinical Nutrition
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 657 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf